Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

How epileptogenic are temporal encephaloceles?
Miller, John W. , Van Gompel, Jamie J, Gompel, Jamie J. Van

Neurology | September 26, 2015 | Volume: 85 | Issue: 17 | Pages: 1440-1441

10.1212/wnl.0000000000002073 | PMID 26408494 Get It

Mixed lineage kinase 3 mediates release of C‐X‐C motif ligand 10–bearing chemotactic extracellular vesicles from lipotoxic hepatocytes
Ibrahim, Samar H. , Tomita, Kyoko, Bronk, Steven F., Werneburg, Nathan W., Goodfellow, Val S., Malhi, Harmeet , Hirsova, Petra , Harrison, Stephen A. , Gores, Gregory J. , Ibrahim, Samar H

Hepatology | September 25, 2015 | Volume: 63 | Issue: 3 | Pages: 731-744

10.1002/hep.28252 | PMID 26406121 Get It

Mixed lineage kinase 3 (MLK3) deficiency reduces macrophage‐associated inflammation in a murine model of nonalcoholic steatohepatitis (NASH). However, the mechanistic links between MLK3 activation in hepatocytes and macrophage‐driven inflammation in NASH are uncharted. Herein, we report that MLK3 mediates the release of (C‐X‐C motif) ligand 10 (CXCL10)‐laden extracellular vesicles (EVs) from lipotoxic hepatocytes, which induce macrophage chemotaxis. Primary mouse hepatocytes (PMHs) and Huh7 cells were treated with palmitate or lysophosphatidylcholine (LPC). Released EVs were isolated by differential ultracentrifugation. LPC treatment of PMH or Huh7 cells induced release of EVs, which was prevented by either genetic or pharmacological inhibition of MLK3. Mass spectrometry identified the potent chemokine, CXCL10, in the EVs, which was markedly enriched in EVs isolated from LPC‐treated hepatocytes versus untreated cells. Green fluorescent protein (GFP)‐tagged CXCL10 was present in vesicular structures and colocalized with the red fluorescent protein (RFP)‐tagged EV marker, CD63, after LPC treatment of cotransfected Huh‐7 cells. Either genetic deletion or pharmacological inhibition of MLK3 prevented CXCL10 enrichment in EVs. Treatment of mouse bone‐marrow–derived macrophages with lipotoxic hepatocyte‐derived EVs induced macrophage chemotaxis, an effect blocked by incubation with CXCL10‐neutralizing antisera. MLK3‐deficient mice fed a NASH‐inducing diet had reduced concentrations of total plasma EVs and CXCL10 containing EVs compared to wild‐type mice. Conclusions: During hepatocyte lipotoxicity, activated MLK3 induces the release of CXCL10‐bearing vesicles from hepatocytes, which are chemotactic for macrophages. (Hepatology 2016;63:731–744)
Exercise training, Sleep and the Heart
Aiello, Kenneth D. , Mookadam, Farouk , Mookadam, Martina

Future Cardiology | September 25, 2015 | Volume: 11 | Issue: 5 | Pages: 507-509

10.2217/fca.15.30 | PMID 26403177 Get It

Improving translation success of cell‐based therapies in orthopaedics
Bara, Jennifer J., Herrmann, Marietta , Evans, Christopher H. , Miclau, Theodore , Ratcliffe, Anthony , Richards, R. Geoff

Journal of Orthopaedic Research | September 25, 2015 | Volume: 34 | Issue: 1 | Pages: 17-21

10.1002/jor.23055 | PMID 26403666 Get It

ABSTRACTThere is a clear discrepancy between the growth of cell therapy and tissue engineering research in orthopaedics over the last two decades and the number of approved clinical therapies and products available to patients. At the 2015 annual meeting of the Orthopaedic Research Society, a workshop was held to highlight important considerations from the perspectives of an academic scientist, clinical researcher, and industry representative with the aim of helping researchers to successfully translate their ideas into clinical and commercial reality. Survey data acquired from workshop participants indicated an overall positive opinion on the future potential of cell‐based therapies to make a significant contribution to orthopaedic medicine. The survey also indicated an agreement on areas requiring improvement in the development of new therapies, specifically; increased support for fundamental research and education and improved transparency of regulatory processes. This perspectives article summarises the content and conclusions of the workshop and puts forward suggestions on how translational success of cell‐based therapies in orthopaedics may be achieved. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:17–21, 2016.
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
Rosenthal, Allison , Kumar, Shaji , Laubach, Jacob P. , Vij, Ravi , Dueck, Amylou C. , Gano, Katherine, Stewart, A. Keith, Dueck, A. C. , Rosenthal, Allison , Hofmeister, Craig C.

British Journal of Haematology | September 25, 2015 | Volume: 174 | Issue: 2 | Pages: 323-325

10.1111/bjh.13765 | PMID 26403323 Get It

Cerebrovascular Manifestations of Hereditary Hemorrhagic Telangiectasia
Brinjikji, Waleed , Sorenson, Thomas J. , Sorenson, Thomas, Iyer, Vivek , Lanzino, Giuseppe

Stroke | September 25, 2015 | Volume: 46 | Issue: 11 | Pages: 3329-3337

10.1161/strokeaha.115.010984 | PMID 26405205 Get It

Familial predisposition and genetic risk factors for lymphoma
Cerhan, James R. , Slager, Susan L. , Cerhan, James R , Slager, Susan L

Blood | September 25, 2015 | Volume: 126 | Issue: 20 | Pages: 2265-2273

10.1182/blood-2015-04-537498 | PMID 26405224 Get It

Abstract Our understanding of familial predisposition to lymphoma (collectively defined as non-Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and chronic lymphocytic leukemia [CLL]) outside of rare hereditary syndromes has progressed rapidly during the last decade. First-degree relatives of NHL, HL, and CLL patients have an ∼1.7-fold, 3.1-fold, and 8.5-fold elevated risk of developing NHL, HL, and CLL, respectively. These familial risks are elevated for multiple lymphoma subtypes and do not appear to be confounded by nongenetic risk factors, suggesting at least some shared genetic etiology across the lymphoma subtypes. However, a family history of a specific subtype is most strongly associated with risk for that subtype, supporting subtype-specific genetic factors. Although candidate gene studies have had limited success in identifying susceptibility loci, genome-wide association studies (GWAS) have successfully identified 67 single nucleotide polymorphisms from 41 loci, predominately associated with specific subtypes. In general, these GWAS-discovered loci are common (minor allele frequency >5%), have small effect sizes (odds ratios, 0.60-2.0), and are of largely unknown function. The relatively low incidence of lymphoma, modest familial risk, and the lack of a screening test and associated intervention, all argue against active clinical surveillance for lymphoma in affected families at this time.
IL17 Functions through the Novel REG3β–JAK2–STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer
Loncle, Céline, Bonjoch, Laia , Folch‐Puy, Emma , López‐Millán, Belén , Lac, Sophie, Molejon, María Inés , Chuluyán, Eduardo , Cordelier, Pierre , Dubus, Pierre , Lomberk, Gwen , Closa, Daniel , Urrutia, Raúl , Iovanna, Juan , Lomberk, Gwen L

Cancer Research | September 24, 2015 | Volume: 75 | Issue: 22 | Pages: 4852-4862

10.1158/0008-5472.can-15-0896 | PMID 26404002 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) offers an optimal model for discovering “druggable” molecular pathways that participate in inflammation-associated cancer development. Chronic pancreatitis, a common prolonged inflammatory disease, behaves as a well-known premalignant condition that contributes to PDAC development. Although the mechanisms underlying the pancreatitis-to-cancer transition remain to be fully elucidated, emerging evidence supports the hypothesis that the actions of proinflammatory mediators on cells harboring Kras mutations promote neoplastic transformation. Recent elegant studies demonstrated that the IL17 pathway mediates this phenomenon and can be targeted with antibodies, but the downstream mechanisms by which IL17 functions during this transition are currently unclear. In this study, we demonstrate that IL17 induces the expression of REG3β, a well-known mediator of pancreatitis, during acinar-to-ductal metaplasia and in early pancreatic intraepithelial neoplasia (PanIN) lesions. Furthermore, we found that REG3β promotes cell growth and decreases sensitivity to cell death through activation of the gp130-JAK2-STAT3-dependent pathway. Genetic inactivation of REG3β in the context of oncogenic Kras-driven PDAC resulted in reduced PanIN formation, an effect that could be rescued by administration of exogenous REG3β. Taken together, our findings provide mechanistic insight into the pathways underlying inflammation-associated pancreatic cancer, revealing a dual and contextual pathophysiologic role for REG3β during pancreatitis and PDAC initiation. Cancer Res; 75(22); 4852–62. ©2015 AACR.
An unusual cause of ascites
Jha, Lokesh K. , Dingli, David , Dingli, David

Blood | September 24, 2015 | Volume: 126 | Issue: 13 | Pages: 1629-1629

10.1182/blood-2015-06-649780 | PMID 26668859 Get It